Literature DB >> 25653453

Dynamics of the cytotoxic T cell response to a model of acute viral infection.

William S DeWitt1, Ryan O Emerson1, Paul Lindau2, Marissa Vignali1, Thomas M Snyder1, Cindy Desmarais1, Catherine Sanders1, Heidi Utsugi3, Edus H Warren3, Juliana McElrath3, Karen W Makar3, Anna Wald4, Harlan S Robins5.   

Abstract

UNLABELLED: A detailed characterization of the dynamics and breadth of the immune response to an acute viral infection, as well as the determinants of recruitment to immunological memory, can greatly contribute to our basic understanding of the mechanics of the human immune system and can ultimately guide the design of effective vaccines. In addition to neutralizing antibodies, T cells have been shown to be critical for the effective resolution of acute viral infections. We report the first in-depth analysis of the dynamics of the CD8(+) T cell repertoire at the level of individual T cell clonal lineages upon vaccination of human volunteers with a single dose of YF-17D. This live attenuated yellow fever virus vaccine yields sterile, long-term immunity and has been previously used as a model to understand the immune response to a controlled acute viral infection. We identified and enumerated unique CD8(+) T cell clones specifically induced by this vaccine through a combined experimental and statistical approach that included high-throughput sequencing of the CDR3 variable region of the T cell receptor β-chain and an algorithm that detected significantly expanded T cell clones. This allowed us to establish that (i) on average, ∼ 2,000 CD8(+) T cell clones were induced by YF-17D, (ii) 5 to 6% of the responding clones were recruited to long-term memory 3 months postvaccination, (iii) the most highly expanded effector clones were preferentially recruited to the memory compartment, and (iv) a fraction of the YF-17D-induced clones could be identified from peripheral blood lymphocytes solely by measuring clonal expansion. IMPORTANCE: The exhaustive investigation of pathogen-induced effector T cells is essential to accurately quantify the dynamics of the human immune response. The yellow fever vaccine (YFV) has been broadly used as a model to understand how a controlled, self-resolving acute viral infection induces an effective and long-term protective immune response. Here, we extend this previous work by reporting the identity of activated effector T cell clones that expand in response to the YFV 2 weeks postvaccination (as defined by their unique T cell receptor gene sequence) and by tracking clones that enter the memory compartment 3 months postvaccination. This is the first study to use high-throughput sequencing of immune cells to characterize the breadth of the antiviral effector cell response and to determine the contribution of unique virus-induced clones to the long-lived memory T cell repertoire. Thus, this study establishes a benchmark against which future vaccines can be compared to predict their efficacy.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25653453      PMCID: PMC4442358          DOI: 10.1128/JVI.03474-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Immunological mechanisms of vaccination.

Authors:  Bali Pulendran; Rafi Ahmed
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

2.  Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes.

Authors:  Evan W Newell; Natalia Sigal; Sean C Bendall; Garry P Nolan; Mark M Davis
Journal:  Immunity       Date:  2012-01-27       Impact factor: 31.745

3.  Site-directed mutations in the VDJ junctional region of a T cell receptor beta chain cause changes in antigenic peptide recognition.

Authors:  I Engel; S M Hedrick
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

Review 4.  Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines.

Authors:  Rafi Ahmed; Rama S Akondy
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

5.  The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.

Authors:  Rama S Akondy; Nathan D Monson; Joseph D Miller; Srilatha Edupuganti; Dirk Teuwen; Hong Wu; Farah Quyyumi; Seema Garg; John D Altman; Carlos Del Rio; Harry L Keyserling; Alexander Ploss; Charles M Rice; Walter A Orenstein; Mark J Mulligan; Rafi Ahmed
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

6.  Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response.

Authors:  Kim Blom; Monika Braun; Martin A Ivarsson; Veronica D Gonzalez; Karolin Falconer; Markus Moll; Hans-Gustaf Ljunggren; Jakob Michaëlsson; Johan K Sandberg
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

7.  E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence.

Authors:  Eva Lee; Mario Lobigs
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

8.  Virus-specific CD8+ T-cell memory determined by clonal burst size.

Authors:  S Hou; L Hyland; K W Ryan; A Portner; P C Doherty
Journal:  Nature       Date:  1994-06-23       Impact factor: 49.962

9.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

10.  IMGT®, the international ImMunoGeneTics information system® 25 years on.

Authors:  Marie-Paule Lefranc; Véronique Giudicelli; Patrice Duroux; Joumana Jabado-Michaloud; Géraldine Folch; Safa Aouinti; Emilie Carillon; Hugo Duvergey; Amélie Houles; Typhaine Paysan-Lafosse; Saida Hadi-Saljoqi; Souphatta Sasorith; Gérard Lefranc; Sofia Kossida
Journal:  Nucleic Acids Res       Date:  2014-11-05       Impact factor: 19.160

View more
  69 in total

1.  Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Authors:  Christoph Groth; Lenneke F J van Groningen; Tiago R Matos; Manita E Bremmers; Frank W M B Preijers; Harry Dolstra; Christian Reicherts; Nicolaas P M Schaap; Eric H G van Hooren; Joanna IntHout; Rosalinde Masereeuw; Mihai G Netea; John E Levine; George Morales; James L Ferrara; Nicole M A Blijlevens; Ypke V J M van Oosterhout; Matthias Stelljes; Walter J F M van der Velden
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-03       Impact factor: 5.742

2.  Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire.

Authors:  Ryan O Emerson; William S DeWitt; Marissa Vignali; Jenna Gravley; Joyce K Hu; Edward J Osborne; Cindy Desmarais; Mark Klinger; Christopher S Carlson; John A Hansen; Mark Rieder; Harlan S Robins
Journal:  Nat Genet       Date:  2017-04-03       Impact factor: 38.330

3.  Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.

Authors:  Sumit K Subudhi; Ana Aparicio; Jianjun Gao; Amado J Zurita; John C Araujo; Christopher J Logothetis; Salahaldin A Tahir; Brinda R Korivi; Rebecca S Slack; Luis Vence; Ryan O Emerson; Erik Yusko; Marissa Vignali; Harlan S Robins; Jingjing Sun; James P Allison; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

4.  Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.

Authors:  Devalingam Mahalingam; Grey A Wilkinson; Kevin H Eng; Paul Fields; Patrick Raber; Jennifer L Moseley; Karol Cheetham; Matt Coffey; Gerard Nuovo; Pawel Kalinski; Bin Zhang; Sukeshi Patel Arora; Christos Fountzilas
Journal:  Clin Cancer Res       Date:  2019-11-06       Impact factor: 12.531

Review 5.  Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations.

Authors:  Jesse J Salk; Michael W Schmitt; Lawrence A Loeb
Journal:  Nat Rev Genet       Date:  2018-03-26       Impact factor: 53.242

6.  The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients.

Authors:  Arjun Khunger; Julie A Rytlewski; Paul Fields; Erik C Yusko; Ahmad A Tarhini
Journal:  Oncoimmunology       Date:  2019-08-20       Impact factor: 8.110

Review 7.  Human T Cell Development, Localization, and Function throughout Life.

Authors:  Brahma V Kumar; Thomas J Connors; Donna L Farber
Journal:  Immunity       Date:  2018-02-20       Impact factor: 31.745

8.  Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.

Authors:  Chandra Sekhar Boddupalli; Noffar Bar; Krishna Kadaveru; Michael Krauthammer; Natopol Pornputtapong; Zifeng Mai; Stephan Ariyan; Deepak Narayan; Harriet Kluger; Yanhong Deng; Rakesh Verma; Rituparna Das; Antonella Bacchiocchi; Ruth Halaban; Mario Sznol; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  JCI Insight       Date:  2016-12-22

9.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Authors:  Nadeem Riaz; Jonathan J Havel; Vladimir Makarov; Alexis Desrichard; Walter J Urba; Jennifer S Sims; F Stephen Hodi; Salvador Martín-Algarra; Rajarsi Mandal; William H Sharfman; Shailender Bhatia; Wen-Jen Hwu; Thomas F Gajewski; Craig L Slingluff; Diego Chowell; Sviatoslav M Kendall; Han Chang; Rachna Shah; Fengshen Kuo; Luc G T Morris; John-William Sidhom; Jonathan P Schneck; Christine E Horak; Nils Weinhold; Timothy A Chan
Journal:  Cell       Date:  2017-10-12       Impact factor: 41.582

10.  Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.

Authors:  Erik Yusko; Marissa Vignali; Richard K Wilson; Elaine R Mardis; F Stephen Hodi; Christine Horak; Han Chang; David M Woods; Harlan Robins; Jeffrey Weber
Journal:  Cancer Immunol Res       Date:  2019-01-11       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.